|
2022 Journal Article Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trialRobledo, Kristy P, Tarnow-Mordi, William O, Rieger, Ingrid, Suresh, Preeti, Martin, Andrew, Yeung, Carbo, Ghadge, Alpana, Liley, Helen G, Osborn, David, Morris, Jonathan, Hague, Wendy, Kluckow, Martin, Lui, Kei, Soll, Roger, Cruz, Melinda, Keech, Anthony, Kirby, Adrienne, Simes, John, on behalf of the APTS Childhood Follow-up Study collaborators and Gardener, Glenn (2022). Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trial. The Lancet Child and Adolescent Health, 6 (3), 150-157. doi: 10.1016/S2352-4642(21)00373-4 |
|
2021 Journal Article Quantifying the advantages of conducting a prospective meta-analysis (PMA): a case study of early childhood obesity preventionSeidler, A. L., Hunter, Kylie E., Espinoza, D., Mihrshahi, S., Askie, L. M., Askie, Lisa M., on behalf of the EPOCH Collaboration, Espinoza, David, Martin, Andrew, Daniels, Lynne A., Mihrshahi, Seema, Taylor, Rachael, Wen, Li Ming, Campbell, Karen, Hesketh, Kylie D., Rissel, Chris, Taylor, Barry, Magarey, Anthea, Seidler, Anna Lene and Baur, Louise A. (2021). Quantifying the advantages of conducting a prospective meta-analysis (PMA): a case study of early childhood obesity prevention. Trials, 22 (1) 78, 1-8. doi: 10.1186/s13063-020-04984-x |
|
2021 Journal Article Reacting to prognostic covariate imbalance in randomised controlled trialsCoskinas, Xanthi, Schou, I. Manjula, Simes, John and Martin, Andrew (2021). Reacting to prognostic covariate imbalance in randomised controlled trials. Contemporary Clinical Trials, 110 106544, 1-7. doi: 10.1016/j.cct.2021.106544 |
|
2021 Journal Article ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Emmett, Louise, Subramaniam, Shalini, Joshua, Anthony M., Crumbaker, Megan, Martin, Andrew, Zhang, Alison Y., Rana, Nisha, Langford, Ailsa, Mitchell, Jenna, Yip, Sonia, Francis, Roslyn, Hofman, Michael S., Sandhu, Shahneen, Azad, Arun, Gedye, Craig, McJannett, Margaret, Stockler, Martin R. and Davis, Ian D. (2021). ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU International, 128 (5), 642-651. doi: 10.1111/bju.15491 |
|
2021 Journal Article Do ethnic patients report longer lung cancer intervals than Anglo-Australian patients?: Findings from a prospective, observational cohort studyMazza, Danielle, Lin, Xiaoping, Walter, Fiona M., Young, Jane M., Barnes, David J., Mitchell, Paul L., Brijnath, Bianca, Martin, Andrew, O'Byrne, Kenneth J. and Emery, Jon D. (2021). Do ethnic patients report longer lung cancer intervals than Anglo-Australian patients?: Findings from a prospective, observational cohort study. European Journal of Cancer Care, 30 (6) e13492, 1-11. doi: 10.1111/ecc.13492 |
|
2021 Journal Article Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapySweeney, Christopher J., Martin, Andrew J., Stockler, Martin R., Begbie, Stephen, Chi, Kim N., Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E., Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin M., McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy, Pook, David W., Reaume, M. Neil, Sandhu, Shahneen K., Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Tu, Emily, Vera-Badillo, Francisco, Williams, Scott G., Yip, Sonia ... Davis, Ian D. (2021). Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 80 (3), 275-279. doi: 10.1016/j.eururo.2021.05.016 |
|
2021 Journal Article [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialHofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y., McJannett, Margaret M., Stockler, Martin R., Violet, John A. ... TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397 (10276), 797-804. doi: 10.1016/S0140-6736(21)00237-3 |
|
2021 Journal Article Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trialTrinh, Terry, Park, Susanna B., Murray, Jenna, Pickering, Hannah, Lin, Cindy S.-Y., Martin, Andrew, Friedlander, Michael, Kiernan, Matthew C., Goldstein, David and Krishnan, Arun V. (2021). Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial. Supportive Care in Cancer, 29 (2), 1103-1110. doi: 10.1007/s00520-020-05591-x |
|
2021 Journal Article Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon CancerBlinman, Prunella, Martin, Andrew, Jefford, Michael, Goldstein, David, Boadle, David, Morris, Michelle, Tebbutt, Niall, Aiken, Christine, Harkin, Andrea, Segelov, Eva, Haydon, Andrew, Iveson, Tim and Stockler, Martin R. (2021). Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. JNCI Cancer Spectrum, 5 (1) pkaa107, 1-6. doi: 10.1093/jncics/pkaa107 |
|
2021 Journal Article Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEKLau, David K., Luk, Ian Y., Jenkins, Laura J., Martin, Andrew, Williams, David S., Schoffer, Kael L., Chionh, Fiona, Buchert, Michael, Sjoquist, Katrin, Boussioutas, Alex, Hayes, Sarah A., Ernst, Matthias, Weickhardt, Andrew J., Pavlakis, Nick, Tebbutt, Niall C. and Mariadason, John M. (2021). Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK. Molecular Cancer Therapeutics, 20 (4), 704-715. doi: 10.1158/1535-7163.MCT-20-0836 |
|
2020 Journal Article Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell CarcinomaLawrence, Nicola J., Martin, Andrew, Davis, Ian D., Troon, Simon, Sengupta, Shomik, Hovey, Elizabeth, Coskinas, Xanthi, Kaplan, Richard, Smith, Benjamin, Ritchie, Alastair W. S., Meade, Angela, Goh, Jeffrey, Gurney, Howard, Harrison, Michelle, Fife, Kate, Eisen, Tim, Blinman, Prunella and Stockler, Martin R. (2020). Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. Kidney Cancer, 4 (4), 185-195. doi: 10.3233/KCA-200104 |
|
2020 Journal Article Communicating prognostic information: what do oncologists think patients with incurable cancer should be told?Vasista, Anuradha, Stockler, Martin R., Martin, Andrew, Lawrence, Nicola J. and Kiely, Belinda E. (2020). Communicating prognostic information: what do oncologists think patients with incurable cancer should be told?. Internal Medicine Journal, 50 (12), 1492-1499. doi: 10.1111/imj.14739 |
|
2020 Conference Publication DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiationNiazi, T., Williams, S., Davis, I. D., Stockler, M. R., Martin, A., Bracken, K., Roncolato, F., McJannett, M., Horvath, L., Sengupta, S., Hughes, S., McDermott, R., Catto, J., Kelly, P., Vapiwala, N., Parulekar, W. R., Morgan, S., Rendon, R. A. and Sweeney, C. (2020). DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. ESMO Virtual Congress, Electr Network, Sep 19-Oct 18, 2020. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2020.08.2088 |
|
2020 Journal Article Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patientsSmith-Uffen, M. E.S., Johnson, S. B., Martin, A. J., Tattersall, M. H.N., Stockler, M. R., Bell, M. L., Detering, K., Clayton, J. M., Silvester, W., Clarke, S., Vaccaro, L., Beale, P. and Kiely, B. E. (2020). Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients. Supportive Care in Cancer, 28 (7), 3399-3407. doi: 10.1007/s00520-019-05158-5 |
|
2020 Journal Article The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancerWhitford, Hayley S., Kalinowski, Pawel, Schembri, Adrian, Grimison, Peter, Stockler, Martin, Martin, Andrew, Toner, Guy C., Davis, Ian D., Maruff, Paul and Olver, Ian N. (2020). The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer. Supportive Care in Cancer, 28 (7), 3081-3091. doi: 10.1007/s00520-019-05095-3 |
|
2020 Journal Article Changes to aspects of ongoing randomised controlled trials with fixed designsCoskinas, Xanthi, Simes, John, Schou, Manjula, Schou, Manjula and Martin, Andrew James (2020). Changes to aspects of ongoing randomised controlled trials with fixed designs. Trials, 21 (1) 457, 1-8. doi: 10.1186/s13063-020-04374-3 |
|
2020 Journal Article Interventions commenced by early infancy to prevent childhood obesity—The EPOCH Collaboration: An individual participant data prospective meta-analysis of four randomized controlled trialsAskie, Lisa M., Espinoza, David, Martin, Andrew, Daniels, Lynne A., Mihrshahi, Seema, Taylor, Rachael, Wen, Li Ming, Campbell, Karen, Hesketh, Kylie D., Rissel, Chris, Taylor, Barry, Magarey, Anthea, Seidler, Anna Lene, Hunter, Kylie E. and Baur, Louise A. (2020). Interventions commenced by early infancy to prevent childhood obesity—The EPOCH Collaboration: An individual participant data prospective meta-analysis of four randomized controlled trials. Pediatric Obesity, 15 (6) e12618, 1-10. doi: 10.1111/ijpo.12618 |
|
2020 Journal Article The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trialTarnow-Mordi, William O, Abdel-Latif, Mohamed E, Martin, Andrew, Pammi, Mohan, Robledo, Kristy, Manzoni, Paolo, Osborn, David, Lui, Kei, Keech, Anthony, Hague, Wendy, Ghadge, Alpana, Travadi, Javeed, Brown, Rebecca, Darlow, Brian A, Liley, Helen, Pritchard, Margo, Kochar, Anu, Isaacs, David, Gordon, Adrienne, Askie, Lisa, Cruz, Melinda, Schindler, Tim, Dixon, Kerry, Deshpande, Girish, Tracy, Mark, Schofield, Deborah, Austin, Nicola, Sinn, John, Simes, R John ... Espinoza, D. (2020). The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial. The Lancet Child and Adolescent Health, 4 (6), 444-454. doi: 10.1016/S2352-4642(20)30093-6 |
|
2020 Journal Article Older adults' preferred and perceived roles in decision-making about palliative chemotherapy, decision priorities and information preferencesMoth, Erin B., Kiely, Belinda E., Martin, Andrew, Naganathan, Vasi, Della-Fiorentina, Stephen, Honeyball, Florian, Zielinski, Rob, Steer, Christopher, Mandaliya, Hiren, Ragunathan, Abiramy and Blinman, Prunella (2020). Older adults' preferred and perceived roles in decision-making about palliative chemotherapy, decision priorities and information preferences. Journal of Geriatric Oncology, 11 (4), 626-632. doi: 10.1016/j.jgo.2019.07.026 |
|
2020 Journal Article Estimating survival time in older adults receiving chemotherapy for advanced cancerMoth, Erin B., Blinman, Prunella, Stefanic, Natalie, Naganathan, Vasi, Grimison, Peter, Stockler, Martin R., Beale, Philip, Martin, Andrew and Kiely, Belinda E. (2020). Estimating survival time in older adults receiving chemotherapy for advanced cancer. Journal of Geriatric Oncology, 11 (4), 617-625. doi: 10.1016/j.jgo.2019.08.013 |
